25I-NBOMe
4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
Standing risks
- High overdose risk, use cautionconfidence high
- Acute toxicity
- critical
Lethal interactions
By drug class
- MAOIslethal2 mechanismsconfidence high
Dangerous interactions
18 dangerous interactions recorded for this substance.
See the full interactions tableContraindications
Cardiovascular
- cardiovascular diseaseabsolute
Includes hypertension, coronary artery disease, arrhythmias, and heart failure. The compound's α₁ adrenergic activity produces marked cardiovascular stimulation documented in multiple fatal cases.
Neurological
- epilepsyabsolute
Any seizure disorder or history of seizures. The compound directly lowers seizure threshold, and seizures are among the most commonly documented complications of toxicity.
Psychiatric
- psychotic disordersabsolute
Personal or family history of schizophrenia, schizoaffective disorder, or other psychotic disorders. 5-HT₂A agonist class contraindication.
- bipolar disorderabsolute
Personal or family history of bipolar I or bipolar II disorder.
Hepatic
- hepatic impairmentrelative
Liver cirrhosis, severe hepatic insufficiency, or conditions significantly reducing hepatic metabolic capacity.
Pregnancy & Breastfeeding
- pregnancyabsolute
Pregnancy and breastfeeding. No reproductive toxicology studies published for 25I-NBOMe.
Other
- concurrent CYP2D6/CYP3A4 inhibitorsrelative
ketoconazole, ritonavir, clarithromycin, paroxetine, fluoxetine, quinidine
Concurrent use of strong CYP3A4 inhibitors or CYP2D6 inhibitors. Also applies to CYP2D6 poor metabolizers (~5-10% of Caucasian populations) who have inherently reduced clearance.
- concurrent serotonergic medicationsabsolute
SSRIs, SNRIs, MAOIs, tramadol, MDMA
Concurrent use of any serotonergic medication. Includes antidepressants (SSRIs, SNRIs, MAOIs), tramadol, and MDMA.